Targeting HER2 as a therapeutic strategy for breast cancer: A paradigmatic shift of drug development in oncology

M. De Laurentiis, G. Cancello, L. Zinno, E. Montagna, L. Malorni, A. Esposito, R. Pennacchio, L. Silvestro, M. Giuliano, A. Giordano, F. Caputo, A. Accurso, Sabino De Placido

Research output: Contribution to journalArticle

Abstract

Targeted therapies are causing a dramatic change in cancer drug development. Trastuzumab, a humanised recombinant monoclonal antibody that recognizes the extracellular domain of HER2 trans-membrane protein, is among the first target-specific drugs that have been licensed for clinical use and its development represents a model of integration of new agents with classical treatment strategies. In preclinical models, trastuzumab has demonstrated a marked antiproliferative effect and a synergistic action with several chemotherapeutic agents. Monotherapy trials indicate that trastuzumab is active as a single agent in HER2 positive patients, is well tolerated, and is associated with preservation of quality of life (QoL). Furthermore, as first line therapy for metastatic breast cancer overexpressing HER2 receptor, the addition of trastuzumab to taxane-based chemotherapy significantly increased rate of objective response, time to disease progression and survival when compared with chemotherapy alone. Trastuzumab has shown important activity when used with many chemotherapeutic agents such as platinum salts, gemcitabine, vinorelbine and capecitabine and liposomal anthracyclines. Various trials are now ongoing to optimize the use of trastuzumab and to investigate its role in the adjuvant and in the neo-adjuvant setting.

Original languageEnglish
JournalAnnals of Oncology
Volume16
Issue numberSUPPL. 4
DOIs
Publication statusPublished - May 2005

Fingerprint

Breast Neoplasms
Pharmaceutical Preparations
gemcitabine
Therapeutics
Antibodies, Monoclonal, Humanized
Drug Therapy
Anthracyclines
Platinum
Reaction Time
Disease Progression
Trastuzumab
Membrane Proteins
Salts
Quality of Life
Survival
Neoplasms

Keywords

  • Breast cancer
  • HER2
  • Targeted therapy
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeting HER2 as a therapeutic strategy for breast cancer : A paradigmatic shift of drug development in oncology. / De Laurentiis, M.; Cancello, G.; Zinno, L.; Montagna, E.; Malorni, L.; Esposito, A.; Pennacchio, R.; Silvestro, L.; Giuliano, M.; Giordano, A.; Caputo, F.; Accurso, A.; De Placido, Sabino.

In: Annals of Oncology, Vol. 16, No. SUPPL. 4, 05.2005.

Research output: Contribution to journalArticle

De Laurentiis, M. ; Cancello, G. ; Zinno, L. ; Montagna, E. ; Malorni, L. ; Esposito, A. ; Pennacchio, R. ; Silvestro, L. ; Giuliano, M. ; Giordano, A. ; Caputo, F. ; Accurso, A. ; De Placido, Sabino. / Targeting HER2 as a therapeutic strategy for breast cancer : A paradigmatic shift of drug development in oncology. In: Annals of Oncology. 2005 ; Vol. 16, No. SUPPL. 4.
@article{4861d7a429564faa9f108b54cf3a44e4,
title = "Targeting HER2 as a therapeutic strategy for breast cancer: A paradigmatic shift of drug development in oncology",
abstract = "Targeted therapies are causing a dramatic change in cancer drug development. Trastuzumab, a humanised recombinant monoclonal antibody that recognizes the extracellular domain of HER2 trans-membrane protein, is among the first target-specific drugs that have been licensed for clinical use and its development represents a model of integration of new agents with classical treatment strategies. In preclinical models, trastuzumab has demonstrated a marked antiproliferative effect and a synergistic action with several chemotherapeutic agents. Monotherapy trials indicate that trastuzumab is active as a single agent in HER2 positive patients, is well tolerated, and is associated with preservation of quality of life (QoL). Furthermore, as first line therapy for metastatic breast cancer overexpressing HER2 receptor, the addition of trastuzumab to taxane-based chemotherapy significantly increased rate of objective response, time to disease progression and survival when compared with chemotherapy alone. Trastuzumab has shown important activity when used with many chemotherapeutic agents such as platinum salts, gemcitabine, vinorelbine and capecitabine and liposomal anthracyclines. Various trials are now ongoing to optimize the use of trastuzumab and to investigate its role in the adjuvant and in the neo-adjuvant setting.",
keywords = "Breast cancer, HER2, Targeted therapy, Trastuzumab",
author = "{De Laurentiis}, M. and G. Cancello and L. Zinno and E. Montagna and L. Malorni and A. Esposito and R. Pennacchio and L. Silvestro and M. Giuliano and A. Giordano and F. Caputo and A. Accurso and {De Placido}, Sabino",
year = "2005",
month = "5",
doi = "10.1093/annonc/mdi901",
language = "English",
volume = "16",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Targeting HER2 as a therapeutic strategy for breast cancer

T2 - A paradigmatic shift of drug development in oncology

AU - De Laurentiis, M.

AU - Cancello, G.

AU - Zinno, L.

AU - Montagna, E.

AU - Malorni, L.

AU - Esposito, A.

AU - Pennacchio, R.

AU - Silvestro, L.

AU - Giuliano, M.

AU - Giordano, A.

AU - Caputo, F.

AU - Accurso, A.

AU - De Placido, Sabino

PY - 2005/5

Y1 - 2005/5

N2 - Targeted therapies are causing a dramatic change in cancer drug development. Trastuzumab, a humanised recombinant monoclonal antibody that recognizes the extracellular domain of HER2 trans-membrane protein, is among the first target-specific drugs that have been licensed for clinical use and its development represents a model of integration of new agents with classical treatment strategies. In preclinical models, trastuzumab has demonstrated a marked antiproliferative effect and a synergistic action with several chemotherapeutic agents. Monotherapy trials indicate that trastuzumab is active as a single agent in HER2 positive patients, is well tolerated, and is associated with preservation of quality of life (QoL). Furthermore, as first line therapy for metastatic breast cancer overexpressing HER2 receptor, the addition of trastuzumab to taxane-based chemotherapy significantly increased rate of objective response, time to disease progression and survival when compared with chemotherapy alone. Trastuzumab has shown important activity when used with many chemotherapeutic agents such as platinum salts, gemcitabine, vinorelbine and capecitabine and liposomal anthracyclines. Various trials are now ongoing to optimize the use of trastuzumab and to investigate its role in the adjuvant and in the neo-adjuvant setting.

AB - Targeted therapies are causing a dramatic change in cancer drug development. Trastuzumab, a humanised recombinant monoclonal antibody that recognizes the extracellular domain of HER2 trans-membrane protein, is among the first target-specific drugs that have been licensed for clinical use and its development represents a model of integration of new agents with classical treatment strategies. In preclinical models, trastuzumab has demonstrated a marked antiproliferative effect and a synergistic action with several chemotherapeutic agents. Monotherapy trials indicate that trastuzumab is active as a single agent in HER2 positive patients, is well tolerated, and is associated with preservation of quality of life (QoL). Furthermore, as first line therapy for metastatic breast cancer overexpressing HER2 receptor, the addition of trastuzumab to taxane-based chemotherapy significantly increased rate of objective response, time to disease progression and survival when compared with chemotherapy alone. Trastuzumab has shown important activity when used with many chemotherapeutic agents such as platinum salts, gemcitabine, vinorelbine and capecitabine and liposomal anthracyclines. Various trials are now ongoing to optimize the use of trastuzumab and to investigate its role in the adjuvant and in the neo-adjuvant setting.

KW - Breast cancer

KW - HER2

KW - Targeted therapy

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=23844512539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844512539&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdi901

DO - 10.1093/annonc/mdi901

M3 - Article

C2 - 15923434

AN - SCOPUS:23844512539

VL - 16

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 4

ER -